PGY3 - Dr. Sondos Zayed on research and representation in radiation oncology bit.ly/3jYY8q3 Sondos Zayed Schulich WesternU #radonc

I hope this 2nd edition helps those practicing brain and spine radiosurgery and thank you to all authors and my friends and Co editors Sunnybrook Health Sciences Centre

ARREST is underway... pushing the metastatic SABR paradigm to new lengths! bmccancer.biomedcentral.com/articles/10.11…

Despite isotropic margins are widely used in #radonc , there are many situations where this approach is suboptimal 👉 Interesting methodology for computing direction-dependent margins for the development of consensus contouring guidelines arjun sahgal rdcu.be/ciUqb

Thank you to CCTG, all my co investigators, TROG Cancer Research, Sunnybrook Health Sciences Centre, Spine Program, University of Toronto, Radiation Oncology and The Lancet Oncology as sc24 is out and shows 24Gy in 2 sbrt fractions is superior to conv radiation for selected painful spinal metastases

Check out this resident driven initiative leveraging virtual platforms to improve the frequency and quality of staff-resident contour review. Credit Rohann Correa with the Idea and early efforts and @axarifin for leading manuscript prep

Marginal failures after bone SBRT is a thing! This guideline may help target delineation bit.ly/3v85Kfl - 11 cases, 9 #radonc contours international effort 🇨🇦🇺🇸🇨🇭🇦🇺🇰🇷🇳🇱. Suggest a 5mm-10mm intraosseous margin for microscopic disease. Extraosseous margin for cortex breach

How many of those were invitations to submit articles or go to conferences that don’t have anything to do with oncology? For me it’s probably 80%

When we started the trial, we knew that accrual would be difficult in a surgery vs. radiation trial...most of these types of trials fail. (See a paper by Tim Nguyen here: redjournal.org/article/S0360-…) So TORS was only offered on trial, like any new drug would be.

#RedJournal Article: International Multi-institutional Patterns of Contouring Practice and Clinical Target Volume Recommendations for Stereotactic Body Radiotherapy for Non-Spine Bone Metastases. @TimKWin ➡️bit.ly/Nguyen_RedJ

🥳Delighted to announce our all-⭐️ cast of Social Champions for today's @ROECSG Annual Symposium! Follow them for live updates, and use/search #ROECSG22 for the latest in #radonc #MedEd! 🙌 🕙 Countdown to action in T-minus 15 min!!

Nice talk by Dr. Thomas sharing updated framework for core competencies in #radonc residency training (Milestones 2.0). Great example of the importance of ongoing program evaluation and how it can inform meaningful improvements #ROECSG22 #radonc ROECSG (Rad Onc Education Collab Study Group)

Bravo Sondos Zayed! Our #radonc resident-led research program for medical students (ORIoN) adapted to a virtual format in its 4th year due to COVID19. Program still beneficial to residents and students alike vs. historical in-person iterations. #ROECSG22

Very interesting initiative. Would definitely be useful for application reviewers. Nice adaptation of a tool that has worked well in emergency medicine #ROECSG22

Really excited for this one. Looking forward to enrolling patients asap. Great work leading this Melissa O'Neil MRT(T)

Time for Session #2 at #ROECSG22 moderated by Matt Spraker + Jillian Gunther - New Education Programs to Expand #radonc Skillsets What innovations are you excited to see implemented? #ROECSG22

Today in the Red Journal: long-term results of SABR-COMET (>5 years after accrual finished), led by @sjharrow Key messages: - improvement in median OS much bigger than at 1st analysis (originally 13 month gain, now 25 months) - no new toxicity signals authors.elsevier.com/sd/article/S03…

📢JOIN US next week at our #NSBM Webinar: "International Practice Patterns and clinical Target Volume Recommendations for SBRT for Non-Spine Bone Metastases" 🗓️ Thursday, July 21, 2022, 13:00 BST 🥼 Dr. Chia-Lin Tseng and Dr. Tim Nguyen 👉 REGISTER: bit.ly/3OcOgGH

Yesterday, we activated two new RCTs of SABR in the oligo/poly-metastatic space. This one below is SABR-SYNC, enrolling patients with up to 10 metastases and a synchronous primary tumor. It's a phase III, primary endpoint is OS.

ARREST-2 opened for accrual yesterday! This is a new randomized phase 2/3 trial for patients with >10 mets that hopes to challenge the current radiotherapy paradigm for patients with polymetastatic disease. Thanks to the whole team esp Dr. David Palma and Glenn Bauman, MD London Health Sciences Centre